new tirzepatide drug FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA approves new version of

Glucagon-like Peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S

The Risks of Compounded and Unapproved Tirzepatide The success of GLP-1 medications like Tirzepatide has unfortunately led to the rise of unapproved and compounded versions

The clinic answer In a UK clinic, cold-chain storage, stock rotation and expiry checks are routine, so you never have to think about any of this

If the plateau continues for an extended period or causes concern, it might be helpful to reevaluate your habits, lifestyle, or even your medication dosage

A separate 2024 study of 290 adults with obesity given oral semaglutide for three months found that free T3 decreased, free T4 rose slightly, and TSH fell during treatment